Alector, Inc. Payments to Acquire Marketable Securities
Alector, Inc. (ALEC) reported Payments to Acquire Marketable Securities of $79.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Alector, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $27.85M, a 63.39% decline year-over-year.
- Alector, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $51.80M, a 7.15% decline year-over-year.
- Alector, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $81.05M, a 6.43% decline year-over-year.
- Alector, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $58.95M, a 29.27% decline year-over-year.
- Alector, Inc. payments to acquire marketable securities for fiscal 2025 was $271.88M, a 41.87% decline from fiscal 2024.
- Alector, Inc. payments to acquire marketable securities for fiscal 2024 was $467.74M, a 15.22% decline from fiscal 2023.
- Alector, Inc. payments to acquire marketable securities for fiscal 2023 was $551.73M, a 0.93% decline from fiscal 2022.
- Alector, Inc. payments to acquire marketable securities for fiscal 2022 was $556.90M, a 62.17% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $79.66M 10-Q · filed 2026-08-06 | $160.70M derived: sum of 3 quarters · filed 2026-08-06 | $219.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $51.80M 10-Q · filed 2026-05-07 | $132.85M derived: sum of 2 quarters · filed 2026-05-07 | $191.81M derived: sum of 3 quarters · filed 2026-05-07 | $267.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $81.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $140.00M derived: sum of 2 quarters · filed 2026-02-25 | $216.09M derived: sum of 3 quarters · filed 2026-08-06 | $271.88M 10-K · filed 2026-02-25 |
| 2025-09-30 | $58.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $135.04M derived: sum of 2 quarters · filed 2026-08-06 | $190.83M 10-Q · filed 2025-11-06 | $277.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $76.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $131.88M 10-Q · filed 2026-08-06 | $218.50M derived: sum of 3 quarters · filed 2026-08-06 | $301.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $55.79M 10-Q · filed 2026-05-07 | $142.41M derived: sum of 2 quarters · filed 2026-05-07 | $225.77M derived: sum of 3 quarters · filed 2026-05-07 | $327.07M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $86.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $169.97M derived: sum of 2 quarters · filed 2026-02-25 | $271.27M derived: sum of 3 quarters · filed 2026-02-25 | $467.74M 10-K · filed 2026-02-25 |
| 2024-09-30 | $83.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $184.65M derived: sum of 2 quarters · filed 2025-11-06 | $381.12M 10-Q · filed 2025-11-06 | $518.37M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $101.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $297.77M 10-Q · filed 2025-08-07 | $435.02M derived: sum of 3 quarters · filed 2025-08-07 | $580.99M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $196.47M 10-Q · filed 2025-05-08 | $333.72M derived: sum of 2 quarters · filed 2025-05-08 | $479.69M derived: sum of 3 quarters · filed 2025-05-08 | $627.92M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $137.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $283.22M derived: sum of 2 quarters · filed 2025-02-26 | $431.45M derived: sum of 3 quarters · filed 2025-02-26 | $551.73M 10-K · filed 2025-02-26 |
| 2023-09-30 | $145.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $294.20M derived: sum of 2 quarters · filed 2024-11-06 | $414.48M 10-Q · filed 2024-11-06 | $577.03M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $148.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $268.51M 10-Q · filed 2024-08-07 | $431.06M derived: sum of 3 quarters · filed 2025-02-26 | $504.11M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $120.27M 10-Q · filed 2024-05-08 | $282.83M derived: sum of 2 quarters · filed 2025-02-26 | $355.88M derived: sum of 3 quarters · filed 2025-02-26 | $647.06M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $162.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $235.61M derived: sum of 2 quarters · filed 2025-02-26 | $526.78M derived: sum of 3 quarters · filed 2025-02-26 | $556.90M 10-K · filed 2025-02-26 |
| 2022-09-30 | $73.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $364.23M derived: sum of 2 quarters · filed 2023-11-07 | $394.35M 10-Q · filed 2023-11-07 | $598.03M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $291.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $321.29M 10-Q · filed 2023-08-03 | $524.98M derived: sum of 3 quarters · filed 2024-02-27 | $659.61M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $30.11M 10-Q · filed 2023-05-04 | $233.80M derived: sum of 2 quarters · filed 2024-02-27 | $368.44M derived: sum of 3 quarters · filed 2024-02-27 | $373.52M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $203.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $338.32M derived: sum of 2 quarters · filed 2024-02-27 | $343.40M derived: sum of 3 quarters · filed 2024-02-27 | $343.40M 10-K · filed 2024-02-27 |
| 2021-09-30 | $134.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $139.72M derived: sum of 2 quarters · filed 2022-11-08 | $139.72M 10-Q · filed 2022-11-08 | $231.58M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.08M 10-Q · filed 2022-08-04 | $96.94M derived: sum of 3 quarters · filed 2023-02-28 | $204.50M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $91.86M derived: sum of 2 quarters · filed 2023-02-28 | $199.42M derived: sum of 3 quarters · filed 2023-02-28 | $303.90M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $91.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $199.42M derived: sum of 2 quarters · filed 2023-02-28 | $303.90M derived: sum of 3 quarters · filed 2023-02-28 | $506.81M 10-K · filed 2023-02-28 |
| 2020-09-30 | $107.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $212.04M derived: sum of 2 quarters · filed 2021-11-04 | $414.95M 10-Q · filed 2021-11-04 | $533.32M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $104.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $307.39M 10-Q · filed 2021-08-03 | $425.76M derived: sum of 3 quarters · filed 2022-02-24 | $497.55M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $202.91M 10-Q · filed 2021-05-05 | $321.28M derived: sum of 2 quarters · filed 2022-02-24 | $393.07M derived: sum of 3 quarters · filed 2022-02-24 | $465.28M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $118.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $190.16M derived: sum of 2 quarters · filed 2022-02-24 | $262.38M derived: sum of 3 quarters · filed 2022-02-24 | $529.61M 10-K · filed 2022-02-24 |
| 2019-09-30 | $71.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $144.01M derived: sum of 2 quarters · filed 2020-11-10 | $411.24M 10-Q · filed 2020-11-10 | $488.36M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $72.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $339.45M 10-Q · filed 2020-08-11 | $416.56M derived: sum of 3 quarters · filed 2021-02-25 | $543.35M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $267.23M 10-Q · filed 2020-05-13 | $344.35M derived: sum of 2 quarters · filed 2021-02-25 | $471.14M derived: sum of 3 quarters · filed 2021-02-25 | $560.57M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $77.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $203.91M derived: sum of 2 quarters · filed 2021-02-25 | $293.33M derived: sum of 3 quarters · filed 2021-02-25 | $472.24M 10-K · filed 2021-02-25 |
| 2018-09-30 | $126.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $216.22M derived: sum of 2 quarters · filed 2019-11-12 | $395.12M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $89.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $268.33M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $178.90M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |